JonathonBrettCohenMD

Oncology • Atlanta, GA

Hematologic Oncology

Physician

Join to view full profile

Dr. Cohen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cohen's full profile

Already have an account?

Office
1365 Clifton Rd NE
Bldg C
Atlanta, GA 30322
Phone+1 404-778-0519

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013
Ohio State University HospitalResidency, Internal Medicine, 2007 - 2010
University of Florida College of MedicineClass of 2007

Certifications & Licensure

GA State Medical License 2013 - 2026
OH State Medical License 2007 - 2015

Clinical Trials

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2012 Feb 09
Completed
Phase 1, Phase 2
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2016 Jan 01
Terminated
Phase 1
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 1, Phase 2
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Start of enrollment: 2018 Aug 13
Completed
Phase 1, Phase 2
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2018 May 16
Recruiting
Phase 1, Phase 2
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2018 Nov 26
Active, not recruiting
Phase 1, Phase 2
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Start of enrollment: 2019 Apr 11
Active, not recruiting
Phase 2
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Start of enrollment: 2021 Sep 03
Recruiting
Phase 2
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2021 Jan 18
Active, not recruiting
Phase 2
Roles: Contact
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2022 Feb 15
Withdrawn
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

51 citations
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Victor M. Orellana-Noia, Daniel R Reed, A. Mccook, Jeremy M Sen, Christian M Barlow
Blood. 2021-09-27
51 citations
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Krish Patel
The New England Journal of Medicine. 2023-07-06
229 citations
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Yoon Cheah, John M. Pagel
Lancet. 2021-03-06

Journal Articles

Intrathecal Central Nervous System Prophylaxis in Patients with Diffuse Large B-cell Lymphoma at an Academic Healthcare System
Jonathon Cohen, MD, Clinical Lymphoma, Myeloma, & Leukemia

Abstracts/Posters

Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel...
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Expert Perspectives on the Role of BTK Inhibitors in CLL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Aggressive Lymphomas
60th American Society of Hematology Annual Meeting - 12/1/2018
Aggressive Lymphomas
60th American Society of Hematology Annual Meeting - 12/1/2018
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

ASH 2018: Novel Therapies for Relapsed/Refractory Aggressive LymphomasDecember 2018
ASH 2018: Novel Therapies for Relapsed/Refractory Aggressive LymphomasDecember 2018

Press Mentions

Mantle Cell Lymphoma: Optimizing Current TherapiesOctober 28th, 2022
Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma PatientsNovember 29th, 2021
CAR T-cell Therapy: Is It Right for You?July 8th, 2021
Join now to see all